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Contiguous follicular lymphoma and follicular 
lymphoma in situ harboring N-glycosylated sites
Follicular lymphoma in situ (FLIS) is composed of a clonal
B-cell population harboring the typical t(14;18) hallmark of
follicular lymphoma (FL), forming unconventional
BCL2BrightCD10+ cell foci in an otherwise normal reactive
lymph node (LN). The diagnosis of FLIS is made on the for-
tuitous discovery of unconventional BCL2BrightCD10+ cell
foci.1 Several studies recently demonstrated that FLIS are
already advanced precursors in follicular lymphomagene-
sis, but not necessarily committed to malignant transfor-
mation.2,3 However, the relationship between FLIS and FL
still remains unclear, as only a minority (<5%) of FLIS
patients eventually develop FL. This is in line with the usu-
ally indolent progression of the disease, and the genomic
instability observed in FLIS cells, which can engage FL pre-
cursor cells either in an evolutionary malignant process, or
to an evolutionary dead end.4
We report the case of a 35-year old male patient who pre-
sented with a cervical adenopathy. Histological examina-
tion of the excised LN displayed an altered architecture sug-
gestive of FL, consisting of high number of monomorphic
large follicles, uniformly spread in the cortical and
medullary areas. Most follicles contained a predominant
population of small cleaved cells with scant macrophages
and mitoses. The mantle zone was reduced or absent.
However, in a minor cortical area, a few follicles showed
features mimicking residual classical germ cells (GC),
including a smaller size, higher cell polymorphism, and a
preserved mantle zone (Figure 1A). 
The BCL2 immunostaining (clone 100) was negative in
follicles displaying a typical FL pattern. In contrast, follicles
located in the pseudo-residual area were BCL2bright, i.e.
more strongly stained than the surrounding mantle zone
and reactive T cells (Figure 1B). Most follicles were only
slightly positive for Ki67 (Online Supplementary Figure S1A).
Both BCL2–and BCL2+ follicles were CD10 positive (Online
Supplementary Figure S1B) and contained a BCL2/JH break-
point evidenced by fluorescence in situ hybridization
(FISH) (Figure 1C). Taken together these results suggested
the diagnosis of simultaneous occurrence of BCL2– FL
(grade I/II) and of BCL2+ FLIS in the same LN. We decided
to further analyze those two lesions independently, and
performed macrodissection in order to proceed with indi-
vidual molecular analyses when required. Sanger sequenc-
ing revealed that both FLIS and FL shared the same
BCL2/JH sequence at the t(14;18)+ breakpoint, and thus
originated from the same clone (Figure 1D).
We tested two other anti-BCL2 antibodies (E17, SP66)
directed against other epitopes, but the staining remained
BCL2- in the FL area of the LN, similar to the anti-BCL2
antibody (clone 100) staining (Figure 1E and F). We thus
sequenced exons 1 to 3 of the BCL2 gene (B-cell CLL/lym-
phoma 2, NG_009361.1). Punctual mutations, resulting in
amino acid substitutions, were found in the FL component
(Online Supplementary Table S1), and were indeed located in
the targeted aa41 to aa54 epitope of clone 100 (mutations
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Figure 1. Description of BCL2 sta-
tus in both the FLIS and the FL
areas of a cervical lymph node.
(A) Hematoxylin/eosin coloration
showing the FLIS and FL zones.
(B) Histochemical staining of
BCL2 with the E100 clone. The
staining was negative in the ger-
minal center of the FL areas,
whereas it was extremely intense
within the GC of the FLIS contain-
ing area (stronger than BCL2+
cells of the extra follicular zones)
(C) FISH staining with the BCL2
break apart probe (LSI BCL2
break-apart probe, Vysis®) in the
FLIS area. Similar results were
obtained in the FL area. 
(D) Sanger sequencing of the
BCL2/JH breakpoint, and the de
novo inserted sequence, in the
FLIS and FL areas. (E)
Histochemical staining of BCL2
with the E17 clone in the FL area 
(F) Histochemical staining of
BCL2 with the SP66 clone in the
FL area. (G) Energy profile
obtained from the BCL2
sequence obtained from the FLIS
and the FL. Fixation sites of the 3
tested antibodies are mentioned.   
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found in aa45-47), in the aa61 to aa76 epitope of clone E17
(mutation found at position aa64) and in the N-terminal
region epitope of clone SP66 antibodies (mutation in aa32).
None of the registered mutations involved a stop codon.
The FLIS and FL sequences were submitted to 3D-molecule
Viewer (Vector NTI advanced 5.11.1®), which revealed
that the acquired mutations in the FL dissected area result-
ed in an altered energy profile of the BCL2 protein, proba-
bly preventing a proper fixation of most anti-BCL2 antibod-
ies (Figure 1G and Online Supplementary Figure S2). 
We thus determined whether the FL cells expressed at
least the BCL2 transcript. mRNA was extracted from
microdissected FL follicles and qRT-PCR was performed.
An approximately 7-fold relative increase in BCL2 tran-
scripts was found compared to microdissected benign reac-
tive lympadenitis [Log2(BCL2/GAPDH) was 3.7 in FL folli-
cles compared to 0.5 in benign reactive lympadenitis], indi-
cating that the absence of BCL2 staining was not due to
transcriptional downregulation.
Taking into account that the FL follicles were composed
of more than 80% of FL B cells, it is unlikely that contami-
nating T cells could be entirely responsible for this high
level of BCL2 transcription, which is thus likely related to
FL B cells. Although we cannot exclude that a post-tran-
scriptional mechanism could have induced downregulation
of the BCL2 protein, these data are in accordance with the
view of the FL component presenting with multiple muta-
tions inducing a conformational change of the BCL2 pro-
tein, which may or may not have altered BCL2 function.
Sustained activity of activation-induced cytidine deaminase
(AID) has been shown to be partly responsible for somatic
mutations in FL. Indeed, AID expression was present in
both FLIS and FL areas of our sample (Online Supplementary
Figure S3A).  
Despite the concomitant FL/FLIS localization, these alter-
ations were lacking in the FLIS dissection, suggesting that
they were acquired in the FL component after divergence
from a common founder clone. To our knowledge, only
rare cases of FLIS with concomitant FL or DLBCL have
been reported, and are usually observed in distinct LNs.5
These reports suggested that FLIS clones were probably
remnants of an earlier colonization by t(14;18)+ B cells that
have preceded FL.5,6 Our case is reminiscent of previously
reported cases of FLIS associated with FL, in which the
associated FL was often negative for BCL2 protein.5-7 This
suggests either that FLIS is more easily detected in those
cases because of the lack of BCL2 in the FL area, or that
BCL2 mutations are frequently associated with progression
from FLIS to FL, when compared to de novo or sporadic FL. 
To further establish the clonal hierarchy between the
FLIS and FL lesions, we investigated the immunoglobulin
variable heavy chain (VH) gene region of FL cells, a region
frequently mutated in FL.8 The VH region of the FL clone
was identified as IGHV3-48*03/IGHD3-22*01/IGHJ4*02,
with approximately 85.4% homology (+/-0.27) among the
various FL subclones (n=16 analyzed sequences, correspon-
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Figure 2. (A) The IGHV3-48*03/ IGHD3-
22*01/ IGHJ4*02 sequences of the FL
and FLIS were used to perform a hierarchi-
cal tree between clones. (B). Percentage of
mutations found in all the IGHV3-48*03/
IGHD3-22*01/ IGHJ4*02 sequences of the
FL and FLIS samples. Other germinal cen-
ter B cells were used as control to have an
idea of the percentage of mutations that
can be observed on a similar population.   
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ding to 7 different subclones) (Figure 2A and Online
Supplementary Table S2). We backtracked this specific
IGHV3-48*03/ IGHD3-22*01/ IGHJ4*02 sequence in the
FLIS and found the same rearrangement within 3 subclones
(Online Supplementary Table S2). Surprisingly, 2 of the FLIS
subclones were more mutated than the corresponding FL
subclones (82.3%+/-2.3 of homology), confirming a strong
and/or repeated somatic hyper mutation (SHM) activity. In
contrast, when looking at non-identical IGHV3 sequences,
i.e. in distinct VDJ clones isolated from the FLIS area that
did not match the sequence of the FL clone (and possibly
represent infiltrating normal mantle zone B cells), the
homology was of 98.2%+/-2.4 (n=14 sequences) (Figure
2A). In addition, the intra-clonal variability was higher in
the FLIS than in the FL component, which could be due to
a dynamic trafficking, such as multiple GC re-entries of the
FLIS clones. This is in line with two recent reports showing
a subclonal heterogeneity among genomic alterations
observed in FLIS.2,3 Overall, our analysis reveals that the
FLIS and the FL clones have evolved through a divergent
evolution model, which postulates the existence of unique
co-existing lesions and subclone selection, in a way similar
to that reported in FL and relapsed FL9 (Figure 2B). 
Finally, among the mutations at the VH IGHV3-48*03
sites, we observed that some of them were responsible for
the introduction of a recurrent N-glycosylation motif (N-X-
S/T) in both FL and FLIS lesions (Online Supplementary Table
S3). These specific glycosylation sites introduce oligoman-
nose glycans that are characteristic of FL, with an incidence
of nearly 100%. They can occasionally be observed in
some GC-derived tumors other than FL, but are very infre-
quent in normal B cells.10 Notably, a similar “N-I-S” motif
was also found in the CDR2 region of a VH IGHV3-48*03
site sequenced from an FL sample.11
Functionally, added glycans terminate at high mannose,
which might influence the behavior of FLIS or FL cells
through opportunistic interactions between the B-cell
receptor (BCR) with mannose-binding lectin bearing cells.12
The engagement of those lectins with the N-glycosylated
sIg would substitute conventional antigen binding, and
could represent a surrogate for antigen stimulation, provid-
ing necessary signaling for lymphoma cell survival.13 This
chronic signaling through the BCR might not constitute an
“oncogenic hit” per se, but might nonetheless favor the gen-
eration of long-lived FLIS clones, increasing the chance of
accumulating the hits that will further drive clone fate.14 In
addition to this role in B-cell survival, chronic engagement
of N-glycosylated sIg may also contribute to a mucin-
dependent evasion from immune surveillance and the
induction of an immunosuppressive environment around
the tumor.15 Since DC-SIGN and DC-SIGNR are two man-
nose-binding lectins able to bind mannosylated Igs in vitro
and FL cells,13 and which were found, in public data sets, to
be up-regulated in lymphoid organs
(http://biogps.org/#goto=genereport&id=10332) (Online
Supplementary Figure S4A and B), we have investigated their
expression using IHC in our case. Positive immunostaining
was only present in the lymphatic endothelium and sinus
histiocytes, which were not directly in contact with FL cells
(Online Supplementary Figure S3B). Although this result does
not support a stimulation of FL cells by DC-SIGN and DC-
SIGNR, one cannot rule out the possible role of other
lectin-like receptors. In fact, lectins are rarely completely
specific for particular sugars, and it is still unclear which
oligosaccharides are responsible for lectin binding to lym-
phoma cells.12 To conclude, this case provided the opportu-
nity to simultaneously analyze synchronous and contigu-
ous FLIS and FL lesions sharing a common ancestor. This is
the first report showing that N-glycosylation sites can
already be present in an FLIS lesion, adding new informa-
tion to help bridge the gap in our knowledge of the rela-
tionship between genomic instability and the dependency
of FL cells on the micro-environment. 
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